Karyopharm Therapeutics Long Term Debt

The latest long-term debt for KPTI is $210M as of June 2026. That compares with $93M in the prior-year period — up 130.0% year over year. Investors often review this figure alongside Karyopharm Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, KPTI's long-term debt moved from $93M to $210M — a 130.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Karyopharm Therapeutics's operating scale or balance-sheet position.

A long-term debt figure of $210M for KPTI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting KPTI's long-term debt ($210M), review year-over-year change from $93M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Karyopharm Therapeutics's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.